1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Dupixent Set To Dominate Bullous Pemphigoid Space

 
• By Kevin Grogan and Alexandra Shimmings

Argenx has discontinued Vyvgart for the rare skin disease as other potential candidates linger in the very early stages of development.

Quick Facts

No drugs are yet specifically approved for the inflammatory skin disease bullous pemphigoid.

Sanofi's Dupixent is set to dominate the market, having gained an FDA priority review.

Several rivals have fallen by the wayside, while others are further back in development.


It looks as though Sanofi and Regeneron’s Dupixent will be the first approved treatment for bullous pemphigoid (BP) and have the market to itself for years given that closest rival Argenx has pulled the

The US Food and Drug Administration has just accepted for priority review the supplemental biologics license application for Dupixent (dupilumab) to treat adults with BP, which is characterized by intense itch and blisters, reddening of the skin and painful lesions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

More from Business

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

How Much Does Biopharma Contribute To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.